Auvelity is not an SSRI. It belongs to an entirely different class of antidepressants, working through a combination of mechanisms that SSRIs don’t touch. Approved by the FDA in August 2022 for major depressive disorder, Auvelity contains two active ingredients: dextromethorphan (45 mg) and bupropion (105 mg). Neither of these is a selective serotonin reuptake inhibitor.
How Auvelity Actually Works
SSRIs focus on a single job: blocking the reabsorption of serotonin so more of it stays active in the brain. Auvelity takes a broader, multi-target approach. Its primary ingredient, dextromethorphan, blocks NMDA receptors, which are involved in a completely different signaling system built around glutamate, the brain’s main excitatory chemical. Dextromethorphan also activates sigma-1 receptors, which help regulate how brain cells respond to stress.
The second ingredient, bupropion, is classified as an NDRI (norepinephrine-dopamine reuptake inhibitor). It increases levels of norepinephrine and dopamine in the brain. Bupropion does not meaningfully affect serotonin, which is the defining feature of SSRIs. Cleveland Clinic notes this distinction clearly: NDRIs boost norepinephrine and dopamine but do not affect serotonin.
Together, the two drugs hit at least four different targets: NMDA receptors, sigma-1 receptors, norepinephrine reuptake, and dopamine reuptake. Dextromethorphan does have some serotonin activity through reuptake blocking and sigma-1 effects, but this is one piece of a much wider mechanism, not the sole focus the way it is with SSRIs like sertraline or fluoxetine.
Why Bupropion Is Included
Bupropion plays a dual role in Auvelity. Beyond its own antidepressant effects on norepinephrine and dopamine, it serves a critical pharmacological purpose: it slows the breakdown of dextromethorphan in the body. Your liver normally metabolizes dextromethorphan quickly through an enzyme called CYP2D6. Bupropion is a potent inhibitor of that enzyme, which allows dextromethorphan to reach and maintain effective levels in the bloodstream. Without bupropion, dextromethorphan would be cleared too rapidly to produce a sustained antidepressant effect.
Faster Onset Than Traditional Antidepressants
One of the most notable differences between Auvelity and SSRIs is speed. SSRIs typically take four to six weeks before patients notice meaningful improvement. In the ASCEND trial, which compared Auvelity head-to-head against bupropion alone, Auvelity showed statistically significant improvement in depression scores by week two. That advantage held at every measurement point through the end of the six-week study.
The remission numbers were striking. At week six, 46.5% of patients on Auvelity achieved remission, compared to 16.2% on bupropion alone. Response rates (at least a 50% reduction in symptom severity) reached 60.5% with Auvelity versus 40.5% with bupropion. The faster onset is likely tied to the NMDA receptor mechanism, which works through a different biological pathway than the slow serotonin buildup that SSRIs rely on.
Side Effects Compared to SSRIs
Auvelity’s side effect profile looks quite different from what most people associate with SSRIs. The most common adverse effects in clinical trials were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Notably, Auvelity was not associated with sexual dysfunction or weight gain in its clinical trial data. These two side effects are among the most common reasons people stop taking SSRIs, which makes the distinction clinically meaningful for many patients.
The seizure risk inherited from bupropion is an important safety consideration. Auvelity is contraindicated in people with seizure disorders, eating disorders (bulimia or anorexia nervosa), and those undergoing abrupt withdrawal from alcohol, benzodiazepines, or barbiturates. It also cannot be taken with MAOIs due to the risk of dangerous interactions.
How Auvelity Is Taken
The dosing schedule starts with one tablet each morning for the first three days. After that, the dose increases to one tablet twice daily, taken at least eight hours apart. The maximum dose is two tablets per day. Each tablet contains 45 mg of dextromethorphan in an immediate-release layer and 105 mg of bupropion in an extended-release layer, so the two ingredients absorb at different rates by design.
Where Auvelity Fits Among Antidepressants
Auvelity occupies its own category. It is the first FDA-approved oral antidepressant that works primarily through NMDA receptor antagonism. This places it closer in concept to ketamine-based treatments than to SSRIs, SNRIs, or tricyclic antidepressants, though it works through a different receptor interaction than ketamine does. If you’re comparing Auvelity to an SSRI for your own treatment, the key differences are its multi-target mechanism, faster expected onset, different side effect profile, and the seizure-related precautions that come with bupropion.